Role of Hypouricemic Agents in Tumor Lysis Syndrome: A Meta-Analysis

Objective and background: Tumor lysis syndrome (TLS) is a life-threatening emergency demands care of effective outcome with minimal or no side effects. The Hypouricemic agents, including Rasburicase, Allopurinol Febuxostate used for the management TLS. This study was designed to evaluate Role agents by analyzing TLS development rate, control uric acid, Creatinine levels.
 Methods: An extensive electronic data search conducted using all leading scientific databases. Twenty-six studies were selected conduct this study, as per inclusion criteria.
 Results: Odd ratio rate 4.06, 1.24, 1.49 Rusbricase, & administration respectively. 95% confidence interval reported against Uric levels administrating Febuxostate.
 Conclusion: All Febuxostate, are manage Syndrome. However, suitable most intervention dose needs identify better efficacy effects both in Adults Children.